No connection

Search Results

BNGO vs MBAI

BNGO
Bionano Genomics, Inc.
BEARISH
Price
$1.15
Market Cap
$11.7M
Sector
Healthcare
AI Confidence
85%
MBAI
Check-Cap Ltd.
BEARISH
Price
$1.80
Market Cap
$13.1M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
BNGO
--
MBAI
--
Forward P/E
BNGO
-0.46
MBAI
--
P/B Ratio
BNGO
0.22
MBAI
2.8
P/S Ratio
BNGO
0.39
MBAI
--
EV/EBITDA
BNGO
-0.45
MBAI
-2.46

Profitability

Gross Margin
BNGO
45.97%
MBAI
0.0%
Operating Margin
BNGO
-115.89%
MBAI
0.0%
Profit Margin
BNGO
-134.36%
MBAI
0.0%
ROE
BNGO
-78.22%
MBAI
-130.12%
ROA
BNGO
-19.31%
MBAI
-20.82%

Growth

Revenue Growth
BNGO
21.3%
MBAI
--
Earnings Growth
BNGO
--
MBAI
--

Financial Health

Debt/Equity
BNGO
0.35
MBAI
0.04
Current Ratio
BNGO
2.12
MBAI
0.71
Quick Ratio
BNGO
1.14
MBAI
0.71

Dividends

Dividend Yield
BNGO
--
MBAI
--
Payout Ratio
BNGO
0.0%
MBAI
0.0%

AI Verdict

BNGO BEARISH

BNGO exhibits severe financial distress despite modest revenue growth, as reflected in its Piotroski F-Score of 1/9—indicating weak operational and financial health. The absence of an Altman Z-Score and the company's negative profitability metrics (e.g., -134.36% profit margin, -78.22% ROE) signal deep operational inefficiencies and high risk of insolvency. Although the stock shows a recent technical uptick and strong earnings surprise history, these are overshadowed by deteriorating fundamentals, massive losses, and a 5-year price decline of 100%. The lack of a Graham Number and intrinsic value estimate further underscores the absence of a reliable valuation anchor. Analysts have a target price of $5.50, but this is not supported by current fundamentals and appears speculative.

Strengths
21.30% year-over-year revenue growth indicates market traction in a high-growth sector
Gross margin of 45.97% suggests strong pricing power and cost control in product delivery
Recent quarterly earnings surprises (average +42.66%) show potential for better-than-expected execution
Risks
Piotroski F-Score of 1/9 is critically low, signaling severe financial deterioration and poor operational efficiency
Negative ROE (-78.22%) and ROA (-19.31%) reflect deep capital inefficiency and sustained losses
Profit margin of -134.36% and operating margin of -115.89% indicate unsustainable business model at current scale
MBAI BEARISH

MBAI exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a critical lack of revenue. The company has reported losses for 25 consecutive quarters, with a devastating ROE of -130.12% and a Current Ratio of 0.71, indicating an inability to cover short-term liabilities. While the 1-year price performance shows a speculative rally, the underlying fundamentals are non-existent, and the absence of an Altman Z-Score or Graham Number reflects a lack of stable equity or earnings to support a valuation.

Strengths
Very low Debt/Equity ratio (0.04)
Recent reduction in the magnitude of quarterly losses
Strong 1-year price momentum (+175.7%)
Risks
Severe liquidity risk with a Current Ratio of 0.71
Chronic lack of profitability over 25 consecutive quarters
Zero reported profit and operating margins

Compare Another Pair

BNGO vs MBAI: Head-to-Head Comparison

This page compares Bionano Genomics, Inc. (BNGO) and Check-Cap Ltd. (MBAI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile